- Home
- MATH vs OBIO Comparison
MATH vs OBIO Comparison
Compare MATH & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MATH
- OBIO
- Stock Information
- Founded
- MATH 2015
- OBIO 2017
- Country
- MATH Hong Kong
- OBIO United States
- Employees
- MATH N/A
- OBIO N/A
- Industry
- MATH Finance/Investors Services
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- MATH Finance
- OBIO Health Care
- Exchange
- MATH Nasdaq
- OBIO Nasdaq
- Market Cap
- MATH 145.4M
- OBIO 172.1M
- IPO Year
- MATH N/A
- OBIO N/A
- Fundamental
- Price
- MATH $2.67
- OBIO $3.99
- Analyst Decision
- MATH
- OBIO Strong Buy
- Analyst Count
- MATH 0
- OBIO 4
- Target Price
- MATH N/A
- OBIO $14.00
- AVG Volume (30 Days)
- MATH 134.2K
- OBIO 366.4K
- Earning Date
- MATH 12-05-2025
- OBIO 11-12-2025
- Dividend Yield
- MATH N/A
- OBIO N/A
- EPS Growth
- MATH N/A
- OBIO N/A
- EPS
- MATH 0.41
- OBIO N/A
- Revenue
- MATH $44,567,257.00
- OBIO $2,944,000.00
- Revenue This Year
- MATH N/A
- OBIO $31.43
- Revenue Next Year
- MATH N/A
- OBIO $10.87
- P/E Ratio
- MATH $6.54
- OBIO N/A
- Revenue Growth
- MATH 165.86
- OBIO 41.61
- 52 Week Low
- MATH $0.88
- OBIO $2.20
- 52 Week High
- MATH $4.17
- OBIO $6.50
- Technical
- Relative Strength Index (RSI)
- MATH 33.33
- OBIO 60.86
- Support Level
- MATH $2.91
- OBIO $3.67
- Resistance Level
- MATH $3.47
- OBIO $4.01
- Average True Range (ATR)
- MATH 0.22
- OBIO 0.30
- MACD
- MATH -0.04
- OBIO -0.02
- Stochastic Oscillator
- MATH 3.53
- OBIO 82.89
About MATH Metalpha Technology Holding Limited
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.